Novo Nordisk, type 2 diabetes
Bernstein said Novo Nordisk’s (NVO) recently released SOUL study results for Rybelsus in the reduction of major ...
The agency posted documents this week that the drugmaker had requested the drug be placed on the FDA's "Demonstrable ...
As Novo Nordisk’s injectable diabetes-obesity duo Ozempic and Wegovy grab all the limelight, an oral version of the ...
Novo Nordisk faces competition from Eli Lilly in new therapeutic areas. Read why I rate NONOF stock as a hold.
GlobalData on MSN13h
Novo Nordisk plans label expansion for Rybelsus following Phase III winThe oral semaglutide reduced the occurrence of major adverse cardiovascular events (MACE) by 14% in patients with T2D.
Novo Nordisk on Monday reported the oral version of its drug semaglutide reduced the risk of major adverse cardiovascular events in adults with type 2 diabetes by 14% in a large Phase III trial.
Catalent, a leading contract drug manufacturer, issued an open letter Monday to reassure customers that a proposed $16.5 ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Novo Nordisk faces growth deceleration but shows promise. Learn more about NVO stock and why its risk/reward profile may ...
Hosted on MSN6d
European Countries Are Cracking Down on Weight-Loss Drugs Like Wegovy—Could the U.S. Follow?Novo Nordisk, the pharmaceutical company behind the world’s most popular weight-loss injections, is expanding its global ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback